Arbutus Biopharma Corporation (ABUS) News
Filter ABUS News Items
ABUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ABUS News From Around the Web
Below are the latest news stories about ARBUTUS BIOPHARMA CORP that investors may wish to consider to help them evaluate ABUS as an investment opportunity.
Here’s Why Arbutus (ABUS) Surged in Q3Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for Q3 2024 and 13.8% year-t0-date while the S&P 500 Index returned 5.9% and 9.3%, respectively. In addition, please check the fund’s top five holdings to know […] |
Whitefort Capital Sends Letter to Arbutus Biopharma Board of DirectorsNEW YORK, December 03, 2024--Whitefort Capital Management, LP (together with its affiliates, "Whitefort Capital," "us" or "we"), which is a long-term investor and the third largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) ("Arbutus" or the "Company") with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published a letter to the Company’s Board of Directors (the "Board") outlining its views on the actions Arbutus must take in order to preserve a |
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside ChatWARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET. To access the live webcast of t |
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to be presented in late-breaker poster session at AASLD – The Liver Meeting® on Monday, November 18, 2024 WARMINSTER, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveragin |
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BSignificantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensi |
Arbutus to Present at Jefferies London Healthcare ConferenceWARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference: Jefferies London Healthcare Conference: Fireside Chat on November 21, 20 |
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...Arbutus Biopharma Corp (ABUS) showcases significant progress in hepatitis B treatment and maintains a robust cash runway into 2026. |
Q3 2024 Arbutus Biopharma Corp Earnings CallQ3 2024 Arbutus Biopharma Corp Earnings Call |
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue EstimatesArbutus (ABUS) delivered earnings and revenue surprises of 0% and 22.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Arbutus: Q3 Earnings SnapshotWARMINSTER, Pa. AP) — Arbutus Biopharma Corp. ABUS) on Wednesday reported a loss of $19.7 million in its third quarter. |